F. Locatelli

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
F Locatelli, F. L. Locatelli, F. Locatelli, Franco Locatelli
Publication record
1,390 papers · 61,710 citations · H-index 121

PAPERS

Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia.
2023130 citationsauthor #10
Achievement of operational tolerance in a pediatric liver transplant recipient following successful hematopoietic stem cell transplantation from a different donor.
20231 citationsauthor #15
Chemotherapy-free treatment for acute promyelocytic leukemia: the pediatric view of a revolutionary tale
20232 citationsauthor #7
Hematopoietic Stem/Progenitor Cells and Engineering: LONG-TERM DATA ON IMMUNE MONITORING OF CHILDREN GIVEN TCRαβ/CD19 CELL DEPLETED HLA-HAPLOIDENTICAL STEM TRANSPLANTATION (HAPLO-HSCT)
20230 citationsauthor #15
Diagnosis by liver stiffness measurement of sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic stem cell transplantation: results from the Italian multicentric prospective study (ELASTOVOD)
20230 citationsauthor #9
Application of Boolean Algebra for Definition of Myeloid Neoplasms
20230 citationsauthor #3
Gut microbiota diversity before allogeneic hematopoietic stem cell transplantation as a predictor of mortality in children
202344 citationsauthor #17
FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD)
20227 citationsauthor #6
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Award Winners (O001-O007)
20220 citationsauthor #16
Efficacy and Safety of Betibeglogene Autotemcel (beti-cel) Gene Therapy in 63 Patients with Transfusion-Dependent β-Thalassemia (TDT): 7-Year Post-Infusion Follow-up of Phase 1/2 and Phase 3 Studies
20220 citationsauthor #2
Signaling Crosstalks Drive Generation and Regeneration of the Thymus
20226 citationsauthor #5
Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT inborn errors working party analysis.
202248 citationsauthor #27
Comparison of Outcomes in Patients with Cerebral Adrenoleukodystrophy (CALD) Receiving Elivaldogene Autotemcel (eli-cel; Lenti-D) Gene Therapy in Clinical Trials Versus Those Receiving Allogeneic Hematopoietic Stem Cell Transplant in a Contemporaneous Comparator Study
20221 citationsauthor #20
Decellularized esophageal tubular scaffold microperforated by quantum molecular resonance technology and seeded with mesenchymal stromal cells for tissue engineering esophageal regeneration
20225 citationsauthor #25
Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis
202219 citationsauthor #5
Analysis of rare driving events in pediatric acute myeloid leukemia
202214 citationsauthor #10
Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T‐acute lymphoblastic leukemia and T‐lymphoblastic lymphoma (study T2008‐002 NECTAR)
202220 citationsauthor #18
αβT- and B-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation in children with myelodysplastic syndromes
20225 citationsauthor #23
Paediatric Acute Lymphoblastic Leukaemia (ALL)
20221 citationsauthor #2
Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group
20227 citationsauthor #16
CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study
202251 citationsauthor #17
Mother donors improve outcomes after HLA haploidentical transplantation: A Study by the Cellular Therapy and Immunobiology Working Party of the EBMT.
20226 citationsauthor #12
Busulfan–fludarabine- or treosulfan–fludarabine-based myeloablative conditioning for children with thalassemia major
202220 citationsauthor #6
Immune dysregulation associated with co-occurring germline CBL and SH2B3 variants
20229 citationsauthor #15
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters
202214 citationsauthor #16
The response to BTN62b2 booster doses demonstrates that serum antibodies do not predict the establishment of immune B-cell memory in common variable immune deficiencies
20220 citationsauthor #22
Allogeneic hematopoietic stem cell transplantation in leukocyte adhesion deficiency type I and III.
202132 citationsauthor #10
TFG binds LC3C to regulate ULK1 localization and autophagosome formation
202119 citationsauthor #27
Outcome of Children with Wiskott-Aldrich Syndrome (WAS) Given TCR Alpha-Beta/CD19 Depleted Hematopoietic Stem Cell Transplantation (HSCT) from an HLA-Haploidentical Relative
20210 citationsauthor #13
Restoring Iron Homeostasis in Pts Who Achieved Transfusion Independence after Treatment with Betibeglogene Autotemcel Gene Therapy: Results from up to 7 Years of Follow-up
20214 citationsauthor #2
Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)
20211 citationsauthor #2
Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma
202172 citationsauthor #13
AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity
2021115 citationsauthor #44
Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts
202111 citationsauthor #28
Use of Ruxolitinib to control Graft-versus-Host Like Disease in Omenn Syndrome and successfully bridging to HSCT.
20212 citationsauthor #10
CD19 expression in pediatric patients with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia pre‐ and post‐treatment with blinatumomab
20219 citationsauthor #5
Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol
202151 citationsauthor #17
Identification of New Soluble Factors Correlated With the Development of Graft Failure After Haploidentical Hematopoietic Stem Cell Transplantation
202110 citationsauthor #9
Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (Pts) with Glucocorticoid-Refractory Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study
20211 citationsauthor #10
Rhabdoid Tumor Predisposition Syndrome: From Clinical Suspicion to General Management
202137 citationsauthor #11
NPM1 Mutational Status Underlines Different Biological Features in Pediatric AML
20216 citationsauthor #11
Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
202114 citationsauthor #2
Targeting cancer stem cells in medulloblastoma by inhibiting AMBRA1 dual function in autophagy and STAT3 signalling
202133 citationsauthor #30
Impact of treosulfan exposure on early and long-term clinical outcome in pediatric allogeneic HSCT recipients: a prospective multicenter study.
202116 citationsauthor #11
Melanotic Neuroectodermal Tumor of Infancy (MNTI) and Pineal Anlage Tumor (PAT) Harbor A Medulloblastoma Signature by DNA Methylation Profiling
202114 citationsauthor #14
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
2021301 citationsauthor #16
Alphabeta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT) in Children with Myelodysplastic Syndromes
20210 citationsauthor #19
Phase 2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
20211 citationsauthor #5
Radiogenomics prediction for MYCN amplification in neuroblastoma: A hypothesis generating study
202123 citationsauthor #8
Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies
202158 citationsauthor #19
The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies
20211 citationsauthor #10
HLA-haploidentical TCRαβ+/CD19+-depleted stem cell transplantation in children and young adults with Fanconi anemia.
202127 citationsauthor #17
The Role of Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Leukemia
202132 citationsauthor #3
Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies
202146 citationsauthor #11
Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.
202140 citationsauthor #25
Safety of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH): Relationship to Treatment Exposure
20211 citationsauthor #2
COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial
202126 citationsauthor #11
Pivotal Role of Dosimetry in High Activity 131i Mibg Therapy in Patients Affected by High Risk Relapsed Refractory Neuroblastoma: Towards a Deeper Metastatic Response Understanding
20210 citationsauthor #10
Safety and efficacy of brincidofovir for Adenovirus infection in children receiving allogeneic stem cell transplantation: an AIEOP retrospective analyses
202112 citationsauthor #16
Targeting mesenchymal stromal cells plasticity to reroute acute myeloid leukemia course.
202126 citationsauthor #19
The role of the thymus in allogeneic bone marrow transplantation and the recovery of the peripheral T-cell compartment
202132 citationsauthor #5
Childhood cancer in Italy: background, goals, and achievements of the Italian Paediatric Hematology Oncology Association (AIEOP)
202116 citationsauthor #14
Superior Overall Survival with Blinatumomab Versus Chemotherapy As Pre-Transplant Consolidation Treatment in Children with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia (B-ALL): Longer Follow-up (FU) of a Phase 3 Randomized Controlled Trial (RCT)
20211 citationsauthor #1
Potential Impact of Treatment with Inotuzumab Ozogamicin on Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia
20213 citationsauthor #13
Application of Mathematical Logic for Cytogenetic Definition and Risk Stratification of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
20211 citationsauthor #2
Extracorporeal membrane oxygenation in children receiving haematopoietic cell transplantation and immune effector cell therapy: an international and multidisciplinary consensus statement.
202126 citationsauthor #33
Proceedings of the 9th International Symposium on MDS and SAA in Childhood
20211 citationsauthor #41
B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies
202146 citationsauthor #15
Thymic Function and T-Cell Receptor Repertoire Diversity: Implications for Patient Response to Checkpoint Blockade Immunotherapy
202127 citationsauthor #3
Engineered mucoperiosteal scaffold for cleft palate regeneration towards the non-immunogenic transplantation
20219 citationsauthor #12
TMOD-05. GENOME-WIDE DNA METHYLATION PROFILE: A POWERFUL STRATEGY TO RECAPITULATE HETEROGENEITY OF PEDIATRIC BRAIN TUMORS IN PRIMARY CELL LINES
20210 citationsauthor #16
Minimal Residual Disease and Outcome Characteristics in Infant KMT2A-Germline Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol
20210 citationsauthor #18
The role of interferon‐gamma and its signaling pathway in pediatric hematological disorders
202132 citationsauthor #4
The unbalanced p53/SIRT1 axis may impact lymphocyte homeostasis in COVID-19 patients
202141 citationsauthor #12
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
2021276 citationsauthor #1
Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas
202128 citationsauthor #19
Identification of neuroblastoma cell lines with uncommon TAZ+/mesenchymal stromal cell phenotype with strong suppressive activity on natural killer cells
202116 citationsauthor #13
Outcomes of Unmanipulated Haploidentical Transplantation Using Post-Transplant Cyclophosphamide (PT-Cy) in Pediatric Patients With Acute Lymphoblastic Leukemia.
202138 citationsauthor #16
Improvement in Health-Related Quality of Life Following Treatment with Betibeglogene Autotemcel in Patients with Transfusion-Dependent β-Thalassemia Enrolled in Phase 3 Studies
20213 citationsauthor #2
Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study.
202166 citationsauthor #5
Outcome of Allogeneic HSCT after Chemo-Based Conditioning in Infants with Acute Myeloid Leukemia in First Complete Remission: A Multicenter EBMT-PDWP Study
20210 citationsauthor #7
Remission, treatment failure, and relapse in pediatric ALL: An international consensus of the Ponte-di-Legno Consortium.
202160 citationsauthor #15
MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells
202122 citationsauthor #18
Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic/therapeutic target in GD2neg/low neuroblastoma variants
202143 citationsauthor #9
Hemoperfusion with CytoSorb to Manage Multiorgan Dysfunction in the Spectrum of Hemophagocytic Lymphohistiocytosis Syndrome in Critically Ill Children
202115 citationsauthor #12
GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape
202131 citationsauthor #15
COVID-19 – pathogenesis and immunological findings across the clinical manifestation spectrum
20216 citationsauthor #3
Monocyte–macrophage polarization and recruitment pathways in the tumour microenvironment of B‐cell acute lymphoblastic leukaemia
202121 citationsauthor #19
ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism
2021109 citationsauthor #12
CD56, HLA‐DR, and CD45 recognize a subtype of childhood AML harboring CBFA2T3‐GLIS2 fusion transcript
202111 citationsauthor #16
Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome
202132 citationsauthor #28
Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma
202135 citationsauthor #18
Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT
202131 citationsauthor #7
Dendritic Cells: Behind the Scenes of T-Cell Infiltration into the Tumor Microenvironment
202133 citationsauthor #5
Delayed referral of pediatric brain tumors during COVID-19 pandemic
202024 citationsauthor #2
Long-Term Efficacy and Safety of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia: Results in Patients with up to 6 Years of Follow-up
20209 citationsauthor #4
A Phase I study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).
202071 citationsauthor #2
Incidence and Therapeutic Implications of Germline TP53 Mutations in Hypodiploid Childhood Acute Lymphoblastic Leukemia: A Retrospective Analysis of the Italian Cohort
20201 citationsauthor #11
Nutlin-3a Enhances Natural Killer Cell–Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors
202040 citationsauthor #19
Microarray expression studies on bone marrow of patients with Shwachman-Diamond syndrome in relation to deletion of the long arm of chromosome 20, other chromosome anomalies or normal karyotype
20203 citationsauthor #17

TIMELINE

1979 0 citations

1980 14 citations

1985 1 citations

1987 1 citations

1989 10 citations

1990 1 citations

1991 203 citations

1992 42 citations

1993 165 citations

1994 232 citations

1995 723 citations

1996 274 citations

1997 2,778 citations

1998 257 citations

1999 946 citations

2000 497 citations

2001 1,763 citations

2002 1,520 citations

2003 2,704 citations

2004 1,757 citations

2005 2,578 citations

2006 913 citations

2007 1,983 citations

2008 3,969 citations

2009 2,370 citations

2010 2,482 citations

2011 2,390 citations

2012 2,281 citations

2013 2,363 citations

2014 3,763 citations

2015 2,654 citations

2016 3,721 citations

2017 3,070 citations

2018 2,316 citations

2019 2,986 citations

2020 5,402 citations

2021 2,152 citations

2022 233 citations

2023 177 citations

Unknown 77 citations

F. Locatelli

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT